Hepatitis C Clinical Trial
Official title:
Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted Patients: Factors Influencing Treatment Initiation and Seroconversion
The aim of the present study is to estimate the national annual prevalence and incidence of current hepatitis C virus (HCV) infections among opioid dependent individuals in opioid substitution treatment (OST) based on a representative sample of approximately 2,500 outpatients in 100 substitution facilities across Germany. Furthermore, the study aims to describe factors influencing HCV therapy initiation and seroconversion during OST.
In this non-interventional, observational, longitudinal study, data is collected at two time
points. The primary outcome measures HCV prevalence and incidence will be based on
documentation from routine patient care at baseline and 12-month follow-up. Secondary
outcome measures will be investigated by means of surveys of opioid substituted patients and
their clinicians (completed at baseline), as well as data from routine patient care.
The sample size calculation is based on the primary outcome variable of HCV incidence among
OST patients. The literature reports an HCV incidence of about 4/100 person-years +/- 2 new
infections per 100 person-years in this target group. For a partial sample size of (at
least) 32 patients with HCV seroconversion and an observation period of 1 year, 800 HCV
antibody-negative patients are needed as an initial group for observation. Assuming an HCV
antibody prevalence of 68% among OST patients, 2500 patients are needed in total (32%
corresponds to N = 800).
Recruitment of clinicians is conducted via the national Substitution Registry in which all
clinicians in Germany, who hold a qualification to prescribe substitution medication, are
registered. To ensure that all substituting clinicians in Germany are considered in the
present study, the investigators sent study invitations to all 3,356 addresses in the
Substitution Registry as of 31.12.2013. Of the clinicians eligible for participation, a
representative sample of clinician is drawn according to two criteria: 'German Federal
State' (GFS) and 'Number of Patients Per Clinician' (PPC). Using the SPSS Complex Samples
Procedure, clinicians are stratified by GFS and PPC, such that each GFS is represented at
least once, and such that the same proportions of clinicians per GFS and per PPC category
are achieved (to the best of our ability) as in the total sample of clinicians registered in
the Substitution Registry.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Recruiting |
NCT04510246 -
Link Hepatitis C Notifications to Treatment in Tasmania
|
N/A | |
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
Completed |
NCT03109457 -
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
|
||
Completed |
NCT01458054 -
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
|
Phase 1 | |
Completed |
NCT03740230 -
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
|
||
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Completed |
NCT00006301 -
Immune Response to Hepatitis C Virus
|
||
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Recruiting |
NCT04405024 -
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
|
N/A | |
Completed |
NCT04525690 -
Improving Inpatient Screening for Hepatitis C
|
N/A | |
Completed |
NCT04033887 -
Evaluation Study of RDTs Detecting Antibodies Against HCV
|
||
Withdrawn |
NCT04546802 -
HepATocellular Cancer Hcv Therapy Study
|
Phase 3 | |
Active, not recruiting |
NCT02961426 -
Strategic Transformation of the Market of HCV Treatments
|
Phase 2/Phase 3 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Completed |
NCT03186313 -
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
|
Phase 3 | |
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 |